Argenica Therapeutics Ltd (AU:AGN) — Market Cap & Net Worth
Market Cap & Net Worth: Argenica Therapeutics Ltd (AGN)
Argenica Therapeutics Ltd (AU:AGN) has a market capitalization of $15.45 Million (AU$21.84 Million) as of May 6, 2026. Listed on the AU stock exchange, this Australia-based company holds position #25754 globally and #1185 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Argenica Therapeutics Ltd's stock price AU$0.17 by its total outstanding shares 128456712 (128.46 Million). Analyse cash flow conversion of Argenica Therapeutics Ltd to see how efficiently the company converts income to cash.
Argenica Therapeutics Ltd Market Cap History: 2021 to 2026
Argenica Therapeutics Ltd's market capitalization history from 2021 to 2026. Data shows change from $75.89 Million to $15.45 Million (-8.31% CAGR).
Argenica Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Argenica Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
17.82x
Argenica Therapeutics Ltd's market cap is 17.82 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $75.89 Million | $2.50K | -$4.09 Million | 30357.70x | N/A |
| 2022 | $40.90 Million | $1.75 Million | -$4.82 Million | 23.37x | N/A |
| 2023 | $46.35 Million | $2.60 Million | -$5.48 Million | 17.84x | N/A |
| 2024 | $57.26 Million | $3.21 Million | -$7.17 Million | 17.82x | N/A |
Competitor Companies of AGN by Market Capitalization
Companies near Argenica Therapeutics Ltd in the global market cap rankings as of May 6, 2026.
Key companies related to Argenica Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $109.06 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $73.69 Billion USD.
- UCB SA (BR:UCB): Ranked #519 globally with a market cap of $50.85 Billion USD ( €43.50 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #567 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.06 Billion | $429.85 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.69 Billion | $709.21 |
| #519 | UCB SA | BR:UCB | $50.85 Billion | €228.50 |
| #567 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Argenica Therapeutics Ltd Historical Marketcap From 2021 to 2026
Between 2021 and today, Argenica Therapeutics Ltd's market cap moved from $75.89 Million to $ 15.45 Million, with a yearly change of -8.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$15.45 Million | -42.37% |
| 2025 | AU$26.81 Million | -53.17% |
| 2024 | AU$57.26 Million | +23.53% |
| 2023 | AU$46.35 Million | +13.33% |
| 2022 | AU$40.90 Million | -46.11% |
| 2021 | AU$75.89 Million | -- |
End of Day Market Cap According to Different Sources
On May 5th, 2026 the market cap of Argenica Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.45 Million USD |
| MoneyControl | $15.45 Million USD |
| MarketWatch | $15.45 Million USD |
| marketcap.company | $15.45 Million USD |
| Reuters | $15.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Argenica Therapeutics Ltd
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Aus… Read more